The company is developing a drug to treat traumatic brain injury using a molecule extracted from marine macroalgae. This molecule targets the immune system to promote repair after brain trauma. The therapy aims to reduce stimulate the immune cells and enhance neurological recovery. We also work to valorise extraction by-products, ensuring a sustainable, biotech-driven approach to neurorepair. Expertise is sought in polysaccharide chemistry and extraction of molecules at pharmaceutical grade.
Ref.RDRNL20260928033. Una empresa holandesa de software de ciberseguridad busca un coordinador y socios para un proyecto de «Europa Digital» (en el marco de CYBER-11-EULEG) sobre auditorías de cumplimiento automatizadas (CRA, NIS2, RGPD).
A Dutch SME offering and expanding continuous IT security and compliance platform is building a consortium for the Digital Europe call CYBER-11-EULEG (deadline 14 January 2027) to fully automate audits against EU legislation such as the Cyber Resilience Act, NIS2...
Sep 29, 2026
















